United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - hypertension ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. heart failure post-myocardial infarction ramipril capsules usp are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see clinical studies (14.3)]. ramipril is contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). 8.1 pregnancy pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and inc

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: erythrosine; gelatin; indigo carmine; iron oxide black; titanium dioxide; pregelatinised maize starch - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; hypromellose; iron oxide red; sodium stearylfumarate; microcrystalline cellulose - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; hypromellose; pregelatinised maize starch; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose - treatment of hypertension. (data are currently not available to support the use of ramipril winthrop in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: gelatin; indigo carmine; iron oxide black; pregelatinised maize starch; erythrosine; titanium dioxide - treatment of hypertension. (data are currently not available to support the use of ramipril sandoz in renovascular hypertension.) postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mmhg or diastolic blood pressure > 90 mmhg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l: hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: iron oxide red; lactose monohydrate; sodium bicarbonate; sodium stearylfumarate; pregelatinised maize starch; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium stearylfumarate; croscarmellose sodium; sodium bicarbonate; pregelatinised maize starch - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium stearylfumarate; sodium bicarbonate; croscarmellose sodium - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; iron oxide yellow; sodium bicarbonate; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate - ? treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. ,? post mi heart failure ,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.